Studying Markers to Track Kidney Disease in Young Adults with Polycystic Kidney Disease
Measures NOX4 and related markers to judge severity in early polycystic kidney disease.
Plain-language title generated from the registry record
Registry title: NOX4 and Related Biomarkers in ADPKD
Key facts
- Where
- Rochester, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 40 years old?
Source: NCT04630613, who can take part
Where in United States
- Mayo ClinicRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT04630613
- Record updated
- 9 January 2026
- Original description
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).Read full original descriptionShow less
NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
Inclusion: ADPKD (based on Ravine et al. criteria); Class 1 A-E according to imaging classification; Male and female subjects 15 - 40 years of age; Estimated GFR> 70 mL/min/1.73 m2 (CKD-EPI); Ability to provide written, informed consent.
Exclusion: Concomitant systemic disease affecting the kidney; Diabetes mellitus; Class 2 according to imaging classification; Predicted urine protein excretion in >1 g/24 hrs; Use of antioxidants i.e. vitamins, Nrf2 activators; Abnormal urinalysis.